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Abstract: The genome of influenza A viruses (IAV) consists of eight single-stranded negative
sense viral RNAs (vRNAs) encapsidated into viral ribonucleoproteins (vRNPs). It is now well
established that genome packaging (i.e., the incorporation of a set of eight distinct vRNPs into
budding viral particles), follows a specific pathway guided by segment-specific cis-acting packaging
signals on each vRNA. However, the precise nature and function of the packaging signals, and
the mechanisms underlying the assembly of vRNPs into sub-bundles in the cytoplasm and their
selective packaging at the viral budding site, remain largely unknown. Here, we review the diverse
and complementary methods currently being used to elucidate these aspects of the viral cycle.
They range from conventional and competitive reverse genetics, single molecule imaging of vRNPs
by fluorescence in situ hybridization (FISH) and high-resolution electron microscopy and tomography
of budding viral particles, to solely in vitro approaches to investigate vRNA-vRNA interactions at
the molecular level.
Keywords: influenza virus; packaging signal; packaging assay; single-molecule FISH; RNA-RNA
interaction; competitive reverse genetics
1. Introduction
Influenza A viruses (IAVs) are responsible for yearly flu epidemics that cause three to five million
cases of severe illness, claim 250,000 to 500,000 lives annually and greatly impact the global economy.
Increased morbidity and mortality can also result from occasional pandemics, the latest one being in
2009. IAVs are members of the Orthomyxoviridae family. Their genome consists of eight single-stranded
negative sense viral RNA segments (vRNAs), varying in length from 2341 to 890 nucleotides (nt),
numbered from 1 to 8 or named after the main protein they encode. Despite their difference in
length, all vRNAs share the same genetic organization: the functional open reading frame (ORF),
in antisense orientation, is flanked by two non-coding regions (NCRs) that differ in length and in
sequence between vRNAs, except for the 12- and 13-nt long sequences at the 31 and 51 end, respectively,
that are highly conserved between vRNAs and between species (Figure 1a). These sequences are
partially complementary and anneal to form a promoter region bound by the trimeric RNA-dependent
RNA polymerase complex formed by the viral proteins polymerase basic protein 1 (PB1), polymerase
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basic protein 2 (PB2), and polymerase acidic protein (PA) [1]. The rest of the vRNA is encapsidated
by several copies of the nucleoprotein (NP) to form viral ribonucleoproteins (vRNPs) that constitute
independent units for viral transcription and replication [2]. In the late steps of viral replication,
newly synthesized vRNPs are exported from the nucleus and transported towards the apical plasma
membrane where they are incorporated into budding viral particles. Current knowledge about nuclear
export and cytoplasmic transport of the vRNPs to reach budding sites is reviewed in [3].
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Figure 1. Schematic diagram of influenza A viral RNA segments (vRNAs). (a) Genetic organization 
of the influenza A virus (IAV) genomic segments. Each segment contains at least one open reading 
frame  (ORF)  in  antisense  orientation,  flanked  by  segment  specific  non‐coding  regions  (NCRs) 
encompassing untranslated regions (UTR) and conserved unique (U) promoter regions of 12 (U12) 
and  13  (U13)‐nucleotides  (nt)  long;  (b)  Schematic  diagram  of  green  fluorescent  protein 
(GFP)‐reporter vRNAs. The  center portion of  the  coding  region  is  replaced with  the GFP  coding 
region  (green),  flanked by portions of various  lengths of  the corresponding  termini of  the coding 
region of  interest  (white);  (c) Schematic  representation of vRNAs bearing  synonymous mutations 
(orange asterisks)  introduced  into the NCRs and termini of the coding regions. Initiation and stop 
codons are indicated by arrows and triangles, respectively.   
In order to be replication‐competent and fully infectious, IAV particles must incorporate at least 
one copy of each of the eight gene segments. Electron microscopy (EM) of IAVs repeatedly revealed 
that vRNPs were arranged in a “7+1” manner in budding virions, with a central vRNP surrounded 
by seven others [4,5]. The genome of IAVs was found to be haploid with equimolar levels of each 
segment  inside  viral  particles  [6,7].  It  is  now  well  established  that  genome  packaging  (i.e.,  the 
incorporation of a set of eight distinct vRNPs into budding viral particles), follows a specific rather 
than a  random pathway, guided by  segment‐specific  cis‐acting packaging  signals on  each vRNA 
[8,9]. The existence of these packaging signals was initially inferred from the occurrence of defective 
interfering RNAs (DI RNAs) derived from IAV gene segments (for reviews see [8,9]). Such RNAs 
carry large deletions of the central ORFs but systematically preserve the NCRs and the adjacent 3′ 
and 5′ ends of the coding region, are efficiently replicated, and compete with their parental vRNAs 
Fig re 1. Sche atic diagra of influenza A viral RNA segments (vRNAs). (a) Genetic organization of
the influenza A virus (IAV) genomic segments. Each segment contains at least one open reading
fra e ( RF) in antisense orientation, flanked by seg ent specific non-coding regions ( CRs)
enco passing untranslated regions (UTR) and conserved unique (U) pro oter regions of 12 (U12)
and 13 (U13)-nucleotides (nt) long; (b) Schematic diagram of green fluorescent protein (GFP)-reporter
vRNAs. The center portion of the coding region is replaced with the GFP coding region (green), flanked
by portions of various lengths of the corresponding termini of the coding region of interest (white);
(c) Schematic representation of vRNAs bearing synonymous mutations (orange asterisks) introduced
into the NCRs and termini of the coding regions. Initiation and stop codons are indicated by arrows
and triangles, respectively.
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of a set of eight distinct vRNPs into budding viral particles), follows a specific rather than a random
pathway, guided by segment-specific cis-acti g ackaging signals on e ch vRNA [8,9]. The existence
of these packaging signals w s initially i ferred from the occurr nce of defective interfering RNAs
(DI RNAs) derived from I V gene segments (for r vi ws se [8,9]). Such RNAs carry large deletion
of the central ORFs but syst matically preserve the NCRs and the adjacent 31 and 51 ends of the
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coding region, are efficiently replicated, and compete with their parental vRNAs for packaging into
the progeny viruses. More recently, the development of reverse genetics (RG)—i.e., the generation of
recombinant influenza viruses from cloned cDNAs (for a detailed review, see [10])—has been key to
the understanding of various aspects of the biology of IAVs, including packaging of the viral genome.
Expression of the eight viral or viral-like RNAs was achieved from a set of plasmids containing
RNA polymerase I (PolI) promoter sequences and either a PolI terminator or a ribozyme sequence
that generate the correct 51 and 31 ends, respectively. These plasmids were transfected into human
embryonic kidney cells expressing the simian virus 40 (SV40) large T antigen (HEK293T) along with
expression plasmids under the control of the RNA polymerase II (PolII) promoter for, at minima, the
synthesis of the viral PB1, PB2, PA and NP proteins, which results in the reconstitution of vRNPs
and allows the initiation of a viral replication cycle [11,12]. Alternatively, a set of eight bidirectional
pPolI-pPolII plasmids has been used [13].
In this article, we review the diverse experimental approaches available to map the cis-acting
packaging signals on individual vRNAs and to understand how they function to promote the assembly
and packaging of a set of eight distinct vRNAs into viral particles.
2. Mapping of cis-Acting Packaging Signals on Individual vRNAs
Packaging signals were initially coarsely mapped by deletional analysis, and then further
defined by directed mutagenesis. Upon introduction of deletions or mutations (Figure 1b,c) into
a reverse genetics pPolI-driven plasmid, the efficiency with which engineered vRNA molecules
were incorporated either into virus-like particles (VLPs) (Figure 2) or into replication-competent
infectious viruses (Figure 3), was measured. Since RNA molecules adopt functionally important
secondary and tertiary structures, rationalizing mutagenesis in order to maintain structural features
is problematic. Short local secondary structure elements have been predicted for IAV vRNAs [14,15]
and only recently, the secondary structure of a non-structural (NS) gene segment vRNA was inferred
from the combination of experimental data and computer folding [16]. However, naked (protein-free)
RNA was used while it is likely that the secondary structure of IAV vRNAs is heavily influenced by
the encapsidation with NP and the binding of the polymerase [17]. An additional difficulty lies in the
fact that packaging signals extend to the coding sequences and mutagenesis therefore requires the
introduction of synonymous mutations in the ORFs. Interestingly, sequences important for packaging
were generally found to be at least partly conserved, leading to a new approach for rationalized
mutagenesis based on the search for regions containing clusters of codons with a lower frequency of
synonymous mutations than expected from amino acid conservation or codon bias [18,19].
2.1. Incorporation of Reporter vRNAs into VLPs
Partial replacement of the vRNA sequences by a reporter gene, typically GFP (Figure 1b), allows
the detection of the reporter vRNA upon incorporation into a VLP and subsequent delivery into
a host cell (Figure 2). Kawaoka’s group pioneered this single-cycle infectious virus approach with
reporter HA (HA-GFP-HA) [20] or NS (NS-GFP-NS) vRNAs [21] where the GFP coding sequence was
flanked by the NCRs and portions of various length of the coding region derived from both termini
(Figure 1b). HEK293T cells were co-transfected with a pPolI plasmid that drove the expression of
the reporter vRNA, together with the seven other pPolI plasmids and at least the four expression
plasmids for the PB1, PB2, PA, and NP proteins plus the one for the protein(s) replaced by the reporter
gene. The supernatants containing the VLPs were used to infect, for instance, MDCK cells, and the
incorporation efficiency of the vRNA of interest was calculated as the ratio of the number of VLPs
containing the vRNA of interest (i.e., the number of GFP-positive cells) to the total number of infectious
VLPs, commonly assessed by the number of NP- or HA-positive cells detected upon immunostaining
and cell count analysis (Figure 2).
To estimate the incorporation efficiency of vRNAs encoding one of the three polymerase subunits
or the nucleoprotein, the system has to be adapted. Indeed, each of these proteins is needed for the
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expression of the reporter gene upon infection with the VLPs, and therefore it has to be provided in
trans. One option has been to co-infect MDCK cells with the VLPs and a helper virus [22,23]. Then, to
accurately determine the total number of infectious VLPs, it was necessary to use specific HA and/or
NP antibodies that do not recognize the proteins derived from the helper virus (Figure 2). A different
approach was used by Liang et al., who co-transfected HEK293T cells with the pPolI reporter plasmid
together with eight bidirectional pPolI-pPolII plasmids, hence producing VLPs as well as wild-type
helper virus in the supernatant [24]. However, under this particular setting, analysis of the results is
complicated by the fact that the reporter vRNA competes with the wild-type vRNAs for incorporation
into virions.
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Figure  2.  Experimental  strategy  to  study  packaging  of  reporter  vRNAs  into  virus‐like  particles 
(VLPs).  Human  embryonic  kidney  cells  expressing  the  simian  virus  40  (SV40)  large  T  antigen 
(HEK293T) were co‐transfected with the indicated pPolI and expression plasmids, including a pPolI 
plasmid  for expression of  the GFP‐reporter vRNA  (see Figure 1). The grey boxes surrounding  the 
GFP  correspond  to  the  portions  of  coding  regions  under  investigation  by  deletional  analysis. 
Supernatants  containing  the VLPs were used  to  infect,  for  instance, Madin‐Darby  canine  kidney 
Figure 2. Experimental strategy to study packaging of reporter vRNAs into virus-like particles (VLPs).
Human embryonic kidney cells expressing the simian virus 40 (SV40) large T antigen (HEK293T)
were co-transfected with the in icated pPolI and expression plasmids, including a pPolI plasmid for
expression of th GFP-reporter vRNA (s e Figure 1). The grey boxes surrounding the GFP corres ond
to the portions of codi g regions und r investigation by deletional analysis. Supernatants containing
the VLPs were used to infect, f r instance, Madin-Darby canine kidney (MDCK) cells. The reporter
gene m y or may not be incorporated into VLPs, together with the seven other segments. When the
reporter replaced one of the four proteins involved in formation of the vRNPs, helper viruses of a
different genetic background (grey) were usually delivered in trans to provide those functional proteins
in the infected cells. The incorporation efficiency of the vRNA of interest was calculated as the ratio of
the number of GFP-positive cells (i.e., the VLPs containing the vRNA of interest) to the total number of
nucleoprotein (NP)- or hemagglutinin (HA)-positive cells (i.e., the total number of infectious VLPs)
while quantitative reverse transcription polymerase chain reaction (RT-qPCR) allowed quantification of
all vRNA segments. PB1: polymerase basic protein 1; PB2: polymerase basic protein 2; PA: polymerase
acidic protein; NA: neuraminidase; NS1: non-structural protein 1; NS2: non-structural protein 2.
Viruses 2016, 8, 218 5 of 15
Viruses 2016, 8, 218    5 of 15 
 
   
Figure  3.  Experimental  strategies  to  study  packaging  of  engineered  vRNAs  into 
replication‐competent  viruses.  (a)  Incorporation  of  reporter  vRNAs  into  replication‐competent 
viruses.  HEK293T  cells  were  co‐transfected  with  the  indicated  pPolI  and  expression  plasmids, 
including  a  plasmid  carrying  a GFP  gene  flanked  by  the HA  (left  panel)  or NA  (middle  panel) 
packaging sequences.  In  the absence of  functional HA, HA‐GFP‐HA viruses can be  rescued upon 
expression of HA  in transfected cells and grown efficiently  in MDCK cells  that stably express HA 
(left panel). NA‐GFP‐NA viruses were produced and grown efficiently in cells supplemented with 
exogenous sialidase or with low sialic acid content (middle panel). Viruses possessing the vesicular 
stomatitis  virus  G  (VSVG)  protein  or  the  hemagglutinin/esterase/fusion  (HEF)  protein  of  an 
Figure 3. Experim nt l strategies to study pack ging of engineered vRNAs into replication-competent
viruses. (a) Incorporation of reporter vRNAs into replication-competent viruses. HEK293T cells were
co-transfected with the indicated pPolI and expression plasmids, including a plasmid carrying a
GFP gene flanked by the HA (left panel) or NA (middle panel) packaging sequences. In the absence
of functional HA, HA-GFP-HA viruse can be rescue upon expre io of HA in transfected cells
and grown efficiently in MDCK cells that stably express HA (left panel). NA-GFP-NA viruses were
produced and grown efficiently in cells supplemented with exogenous sialidase or with low sialic
acid content (middle panel). Viruses possessing the vesicular stomatitis virus G (VSVG) protein or the
hemagglutinin/esterase/fusion (HEF) protein of an influenza C virus as the surface protein instead
of HA and NA were produced by co-transfection of HEK293T cells with six monodirectional pPolI
plasmids together with the pPolI-HA-(VSVG/HEF)-HA and pPolI-NA-GFP-NA plasmids (right panel).
In all cases, viral particles may contain or not the reporter gene, together with the seven other segments.
The incorporation efficiency of the vRNA of interest was calculated as described in the legend of
Figure 2; (b) Incorporation of vRNAs carrying point mutations into replication-competent viruses.
HEK293T cells were co-transfected with the indicated pPolI and expression plasmids, or bidirectional
pPolI-pPolII plasmids, including a pPolI or pPolI-pPolII plasmid for expression of the vRNA of interest
carrying mutations in the NCRs or synonymous mutations (indicated by asterisks) in the termini of
the coding sequence. Supernatants were used to infect MDCK cells and/or to inoculate embryonated
chicken eggs, the latter being usually performed with the egg-adapted influenza A/Puerto Rico/8/34
(PR8) virus. The vRNA content of viral particles was quantified by RT-qPCR or by densitometry on
silver-stained denaturing polyacrylamide gels (for egg-grown viruses). Phenotypic assays of rescued
viruses were used as an indicator of the disruptive effect of deletions (a) or mutations (b) within vRNAs
on viral growth. TCID50: median tissue culture infective dose; PFU: plaque-forming units.
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2.2. Incorporation of Engineered vRNAs into Replication-Competent Viruses
In the context of replication-competent viruses, deletional analysis with a reporter gene is possible
only with genes that can be compensated for, typically HA and NA (Figure 3a). For example,
recombinant viruses carrying a GFP gene flanked by the HA packaging sequences have been rescued
upon expression of HA in transfected cells and grown efficiently in MDCK cells that stably express the
HA glycoprotein during multiple passages [25] (Figure 3a, left panel). Likewise, a segment containing
a GFP gene flanked by the NA packaging sequences has been incorporated and stably maintained
during viral replication in cells supplemented with exogenous Vibrio cholerae sialidase [26] or in cells
with poor content in sialic acids [27] (Figure 3a, middle panel).
It is also feasible to generate viruses possessing a surface glycoprotein that substitutes for both
HA and NA functions. This was achieved using the vesicular stomatitis virus G (VSVG) protein
by Kawaoka and co-workers [20] and using the hemagglutinin/esterase/fusion (HEF) protein of an
influenza C virus by Palese and co-workers [28]. The VSVG or HEF gene were introduced instead
of the HA coding sequence and flanked by the HA packaging sequences. Such chimeric viruses
can therefore express GFP introduced as an eighth segment, to map the NA packaging sequences
(Figure 3a, right panel).
When the packaging efficiency is assessed in an infectious context, the choice of the reporter
gene is not neutral. Differences were observed between the HA-VSVG-HA and the HA-GFP-HA
viruses in terms of minimal sequences required for efficient incorporation into viral particles [25].
This is likely due to the fact that the VSVG protein was required for attachment and infection and
therefore the packaging of the corresponding segment was, unlike HA-GFP-HA, under positive
selection. To determine whether the length of the vRNA or the sequence of the reporter had any
effect on the packaging, constructs with a single GFP or red fluorescent protein (RFP), or with a
tandem of GFP genes were compared [25]. Although the packaging of all constructs was efficient,
the HA-GFP-GFP-HA segment, whose length is very close to the HA vRNA length, showed a higher
level of incorporation compared to HA-GFP-HA. It is noteworthy that the virus with the HA-RFP-HA
segment could replicate efficiently only when expression of RFP was lost due to non-sense mutations.
Mutational analysis was used to map more precisely the nucleotides that form the packaging
signals [19,21,25,29–31] (Figures 1c and 3b). Using reverse genetics, the effect of mutations has been
looked at broadly by phenotypic characterization of the viruses, or more specifically by quantitative
measurement of the viral RNA content. Analyses of this kind also apply to recombinant viruses
carrying a reporter vRNA as described above.
2.2.1. Phenotypic Characterization of the Viruses
The properties of the wild-type and mutant viruses have also been compared by assessing
the production of infectious virus particles by median tissue culture infective dose (TCID50) assays
or plaque assays. The plaque phenotype is also a marker of the replicative properties of a given
virus and has been used as an indicator of the disruptive effect of mutations on viral growth [29,30].
Hemagglutination titers or particle titers obtained by electron microscopy counting of virions were
used to establish HA/plaque forming units (PFU) or particle/PFU ratios, which helps evaluating
whether the mutations are detrimental or not. Mutants that have a disruptive effect on packaging
usually display an increased particle/PFU ratio as compared to the wild-type [29]. It is noteworthy
that typically observed reductions in viral loads ranged from 1 to 3-logs when grouped point mutations
were tested but never completely abolished the rescue of infectious viruses. This could be due to
the discontinuous nature of the packaging signals along a particular gene segment [18,19,25,29–31],
allowing the loss of certain packaging sequences to be compensated for by others. In addition, the
proposed plasticity in the positioning of the eight vRNPs within virions [32,33] most likely also
increases the chances of correct genome packaging.
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2.2.2. Quantitative Measurement of the Viral RNA Content
The most frequently used method to directly analyze packaging efficiency has been quantification
by quantitative reverse transcription polymerase chain reaction (RT-qPCR) of each of the genomic
segments extracted from purified viral particles [19,29,30], which offers the possibility to analyze
not only the packaging efficiency of the mutated vRNA gene but also that of the other vRNAs
(see below). However, in the absence of standard curves obtained from synthetic vRNAs, only relative
concentrations of RNA can be determined. RT-qPCR data need to be (i) normalized to the total
vRNA amount by equalizing the level of one reference segment; and (ii) compared to the wild-type
virus [19,25]. The latter point makes the assumption that in the wild-type virus, each vRNA is detected
in equimolar ratio. This may not be the case if, for instance, defective vRNAs are not detected by
the RT-qPCR and vary in proportion from segment to segment. The NA segment has commonly
been used as a reference segment, because its packaging appears relatively less constrained compared
to other segments [19,22,34]. When RT-qPCR data are normalized by comparison with standards,
segment/particle ratios can be calculated, using matching particle titers, and compared to the ratios
obtained for the wild-type virus; plaque titer values can also be used to calculate segment/PFU
ratios [29,30]. These are useful parameters, as mutations in a given vRNA can decrease the overall
packaging of all vRNA segments while maintaining equimolar ratios, as shown by Hutchinson and
co-workers for the matrix (M) gene segment vRNA [29].
As an alternative to RT-qPCR analysis, the vRNA content of viral particles has been quantified on
silver-stained denaturing polyacrylamide gels followed by densitometry. This method usually requires
egg-grown viral stocks, in order to get sufficient amounts of vRNAs that should be extracted from
equal numbers of viral particles (preferably physical particles) [29,30,34]. In addition, the accuracy of
densitometry data is subjected to the existence of a linear relationship between the staining intensity
and the amount of nucleic acid that needs to be verified for the concentration range used in the
experiment [29].
2.3. Relevant Experimental Controls
Whether VLPs or replication-competent viruses are used to investigate vRNA incorporation
efficiencies, various assays need to be performed to rule out possible mutation-induced pleiotropic
effects that could provoke defects at earlier stages of the virus life cycle. Typically, the levels of
reporter or mutant vRNAs in plasmid-transfected cells have to be quantified, usually by RT-qPCR
(alternatively by primer extension or Northern blotting), to ensure that equivalent amounts of wild-type
and engineered RNAs are being transcribed and are available in infected cells for packaging into
virions [19,22,30,31]. Likewise, the amounts of reporter protein produced in transfected cells have to be
monitored, to control for potential bias at the post-transcriptional level [22,31]. Wild-type and mutant
viruses can also be investigated for potential defects in trafficking by fluorescence in situ hybridization
(FISH), possibly combined with simultaneous labeling of the nuclear envelope, the plasma membrane,
or other sub-cellular compartments by indirect immunofluorescence.
3. Unraveling the Mechanism for Co-Packaging of Eight Distinct vRNAs
Interestingly, the mutational approach described above has revealed that reduction in
incorporation of a particular mutated vRNA was also accompanied, in some cases, by a decreased
incorporation efficiency of other vRNAs [19,22,25,29,30], strongly suggesting the existence of
intersegment interactions that may drive the assembly process. In the particular case of NP vRNA,
it was shown that the NCRs guarantee incorporation of the vRNA into virus particles while the
previously defined packaging signals (including the NCRs and the termini of the coding sequence)
ensure incorporation of a correct set of vRNPs [35]. Interestingly, the HA NCRs, and more specifically
the 31 NCRs, found to be subtype specific and of varying length and sequence, strongly modulated
virus replication by impacting the level of HA vRNA incorporation, without significantly reducing
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incorporation of the other vRNAs [36]. Altogether, these data suggest that the NCRs are critical for
virion selective incorporation of vRNAs, whilst nucleotides in the coding regions could be involved
in intersegment interactions. In addition, packaging also appears to be a hierarchical process as not
all vRNAs are equally important for efficient genome incorporation: PB2 vRNA is more important
than PB1 and PA vRNAs in the influenza A/WSN/33 strain [22] while PB2, M, PA, and NP vRNAs
play a more important role than the remaining four vRNAs in the packaging process for the influenza
A/Puerto Rico/8/34 (PR8) strain [19,30,34]. A recent study suggests that sequential formation of
vRNP sub-bundles (an assembly of less than eight vRNPs) within the cytoplasm might be required for
efficient packaging of a full set of eight distinct vRNPs [37]. However, it is still unclear whether the
“genome bundling” process is driven by the genome packaging sequences (for details, see [3]).
3.1. Co-Packaging Assays
3.1.1. The Rewiring Approach
To study co-packaging, Palese and co-workers exploited a seven-segmented chimeric PR8, with
no NA segment, but with a segment encoding the HEF protein of an influenza C virus, flanked by
HA packaging sequences [28]. This virus was used to study the role of the PB1, PB2, PA, NP, M,
or NS segment in genome packaging, by generating (i) a set of seven-segmented viruses in which
one of the gene-specific packaging sequences was mutated and replaced functionally with the NA
packaging sequences, leading to a “rewired segment”; and (ii) a matched set of eight-segmented
viruses with an additional gene segment carrying the GFP ORF surrounded by the wild-type packaging
sequences of the PB1, PB2, PA, NP, M, or NS segment [34]. Comparison of the viral growth between
seven-(GFP minus) and eight-(GFP plus) segmented viruses was one of the readouts performed
to assess the role of the packaging sequences of a particular vRNA segment: impairment of viral
growth for the seven-segmented virus but rescued for the eight-segmented virus is an indicator of the
importance, for global packaging, of the gene-specific incorporation sequence that has been targeted.
3.1.2. Competitive Reverse Genetics
The segmented nature of the IAV genome drives the need for a sophisticated and specific
packaging process but also provides the virus with a mechanism to facilitate the exchange of intact gene
segments, in a process named “genetic reassortment”, when two distinct influenza viruses co-infect the
same cell [38]. Alternatively, genetic reassortment can occur after plasmid transfection using two full
sets of RG plasmids for each virus. The genetic reassortment process is clearly biased as all possible
gene combinations (256 when two different viruses co-infect the same cell) are not observed under
natural or experimental conditions and certain gene segments tend to co-segregate [39–43]. Yet, some
rare reassortant genotypes can efficiently be rescued by RG with a defined set of eight plasmids to
transfect. Hence, in an intermediate approach, competitive plasmid transfection with more than eight
(but less than 16) RG plasmids is a tool that has been exploited to investigate co-segregation and
co-packaging of pairs of vRNAs (Figure 4) [43].
The combined use of nine-plasmid reverse genetics and site-directed mutagenesis to construct
chimeric functional gene segments has revealed molecular determinants that drive co-segregation of
pairs of vRNAs ([43] and Gilbertson et al., this issue) (Figure 4). For instance, if precise vRNA/vRNA
interacting sequences have been delineated, trans-compensatory mutants, that need to be silent if
located in the coding sequence(s), can be designed on both RNA partners and tested in four competitive
RG assays, where the wild-type and mutant counterpart for one vRNA compete for incorporation
with either their wild-type or mutant vRNA partner, and vice versa. If the genotype of resulting viral
particles is strongly biased towards either a wild-type or a double compensatory mutant, this is a
strong indication that vRNAs that interact together are preferentially co-packaged [9,44]. Generally,
competitive RG can become a tool to identify associations between vRNAs that are important for
co-packaging during viral budding and/or co-segregation during genetic reassortment.
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Figure 4. Nine-plasmid-based competitive reverse genetics (RG) as a tool to analyze vRNA-vRNA
co-packaging. In nine-plasmid competitive RG experiments, HEK293T cells were co-transfected with
seven bidirectional pPolI-pPolII RG plasmids defining the genetic background and two plasmids
that express competing vRNAs. (a) If two vRNAs (for instance vRNAs 2 and 6, in blue) were found
to co-segregate in an otherwise different genetic background (red) during a genetic reassortment
experiment, the “2-blue:6-blue:other-red” genotype is expected to emerge predominantly during a
nine-plasmid competitive RG experiment; (b) Chimeric constructs (of vRNA 2 for instance) can be used
to delineate the region of the vRNA involved in guiding co-packaging of the two vRNAs. If the region
marked by an asterisk (2Chim*) is the important one for the co-packaging interaction with the vRNA
partner (6, in blue), the wild-type and chimeric genotypes are expected to emerge with approximately
the same frequency; (c) A chimera carrying a region of vRNA 2 that is not important for co-packaging
of the two partner vRNAs (2Chim) is expected to emerge at much lower frequency than the wild-type;
(d) Finally, competition between the two chimeras is expected to be in favor of the one bearing the
region involved in co-packaging of the two vRNA partners.
A limitation of genetic reassortment as a tool to analyze packaging lies in the fact that protein
compatibility can constrain the reassortment process at stages of the viral life cycle other than packaging.
Therefore, the predominance of a given gene combination can occur not because of differences in
co-packaging efficiency but because of differences in fitness of the corresponding reassortant viruses.
Another limitation lies in the relatively small number of viral clones that can be analyzed to date
in order to generate statistically significant results. Indeed, the identification of reassortant viruses
arising from RG experiments requires genotyping of clonal isolates. Classically, vRNAs are extracted
from plaque-purified viruses and reverse transcription-PCR (RT-PCR) products are sequenced [45].
Standard or quantitative PCR can also be performed taking advantage of sequence differences between
the two parental strains if they are heterologous enough. A new method for genotyping reassortant
viruses was recently described, based on the differential melting properties of double-stranded DNA
(dsDNA) PCR amplicons with differences in sequence as little as 1 nt. This high-resolution melting
(HRM) analysis was based on the design of primers that bind to conserved regions in both strains of
interest and surround 50 to 150 nt-long regions that contain one or more sequence differences between
both strains [46]. Compared to the previous approach, HRM may allow discrimination between
segments that are very similar. On the other hand, highly divergent segments such as HA and NA
may not contain enough conservation to allow annealing of the primers to identical regions in both
strains. In the particular case of a mixed population of viruses arising from a defined nine-plasmid
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reassortment experiment as shown in Figure 4, deep sequencing targeting the competing segments
of interest has also been used to give the relative abundance of the two competing genotypes [47].
Pyrosequencing, which can provide quantitative data, is another alternative [48].
3.2. Visualization of vRNP Transport and Bundling
3.2.1. Single-Molecule Fluorescence In Situ Hybridization (smFISH)
Like all hybridization-based techniques, FISH detects RNA molecules using fluorescently labeled
probes that are complementary to the sequence of interest. Single-molecule sensitivity can be achieved
by using several probes targeting different regions of the same RNA. Between 15 and 48 oligonucleotide
probes labeled with a single fluorophore are usually used to probe one RNA species.
The smFISH technology has been applied to surface-immobilized viral particles to estimate the
co-packaging efficiency of two different vRNA segments into viruses, using for instance a mixture
of Cy3- and Cy5-labeled probes against two different RNA segments [49]. The copy number of each
vRNA segment being packaged was also evaluated upon photobleaching analysis [49].
The smFISH technique was also applied to the detection of vRNAs within infected cells, using
for instance two-color [50] or four-color smFISH [37] for the visualization of two or four distinct
vRNA segments, respectively. These approaches gave insights into the trafficking of pre-formed vRNA
complexes from the nucleus to the plasma membrane and are discussed in detail in [3]. Four-color
smFISH probes have been used to test all pair-wise combinations of vRNA segments [37]. Combining
smFISH with immunostaining (or expression of a protein fused to a fluorescent protein) allowed
quantification of the proportion of co-localized vRNAs that are associated with a cellular or a viral
protein [37,50].
Importantly, specificity of smFISH probes needs to be verified on cells expressing a single vRNA
transcript from a pPolI expression plasmid. The distance threshold that defines co-localization needs
to be defined based on the distances between fluorescent spots measured with a positive control
(two labeled probes targeting two regions of the same vRNA molecule) and a negative control
(two labeled probes targeting non-interacting RNA molecules). On a standard microscope this
threshold is usually set around 250 nm, which does not allow to unambiguously conclude that
two vRNAs are physically interacting with each other. Given the high density of vRNAs in infected
cells, it may be difficult to distinguish actual physical interactions from crowding-induced random
proximity. Combining smFISH analysis with fluorescence resonance energy transfer (FRET) or with
super-resolution microscopy [51] could help to overcome this limitation.
The sensitivity and quantitative accuracy of smFISH are also limited. The fact that 100% of
co-localization for probes targeting the same vRNA cannot be achieved [49,50] may be explained by
intrinsic defects of some vRNAs or by the limit of detection of co-localized spots. The quantification of
the copy number of vRNA packaged within influenza virions may be overestimated by self-aggregation
of virus particles (10% of the spots exhibit high number of photobleaching steps) [49]. Finally,
visualization of vRNA segments has been so far restrained to two- or four-color smFISH due to
the limited availability of fluorophores with non-overlapping spectra, thus hindering assessment of the
localization and interactions between more than four vRNA segments within a single cell. Multiplex
smFISH has been achieved by sequential barcoding, where each segment is detected multiple times
through hybridization, imaging, and probe removal cycles, and appears in a different color during
each cycle [52,53].
3.2.2. Electron Microscopy and Tomography
Visualization of budding virions in traverse thin-section by EM has repeatedly revealed that
the eight vRNPs are arranged in a “7+1” manner [5,29,32,33,44]. Cross-sections of budding viral
particles were analyzed by EM to investigate their vRNP content and the ratio of full, partially full
or empty viral particles was determined. Such visualization provided a global qualitative analysis
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of the vRNP content of influenza virions and has been used to assess global packaging defects of
mutant viruses compared to their wild-type counterpart [54]. The shortcomings of this method are the
likelihood that viral particles are sectioned below the longest vRNPs and will thus appear empty, the
fact that the different segments cannot be distinguished from each other, and that, for yet unknown
reasons, the “7+1” architecture is rapidly lost after budding. The analysis of a large number of different
cross-sections is one way to partly correct for these biases.
The arrangement of vRNPs inside influenza A viral particles has also been analyzed by
cryo-electron tomography, which allows to reconstruct the 3D structure of individual ice-embedded
viral particles. Cryo-electron tomography confirmed that influenza virions most commonly contain
eight vRNPs that form a near-parallel bundle where the “7+1” configuration can be observed, with
the length of vRNPs varying from 24 to 110 nm [4]. Based on the fact that differences in length allow
to distinguish most of the vRNPs inside the viral particle, the relative arrangements of vRNPs with
respect to each other was studied [32,33]. Identification of packaged vRNAs could be envisaged
with specifically engineered, easily distinguishable, vRNA segments. The combination of scanning
transmission electron microscopy (STEM) tomography and immuno-EM was also used to assess the
orientation of vRNPs within virions [55].
3.3. In Vitro vRNA-vRNA Interactions Assays
Since the first demonstration of the existence of segment-specific packaging signals by RG, direct
interactions between vRNAs appeared as an attractive hypothesis to explain the selective packaging
mechanism. This hypothesis is reinforced by the fact that no viral or cellular protein specifically
recognizing an IAV segment-specific packaging signal has been identified so far. Furthermore, inside
vRNPs, vRNAs would be largely exposed on the external surface of NP oligomers [17,56,57], allowing
such RNA/RNA interactions to occur. However, demonstrating the existence of specific vRNA-vRNA
interactions in viral particles without prior knowledge of the sequences involved is challenging.
To address this question, in vitro assays have been used as a tool to identify interacting RNA
partners. The vRNAs were synthesized by in vitro transcription, and the interactions between all
possible pairs of vRNAs analyzed using an electrophoretic mobility shift assay. Using such assays,
single and strain-specific interaction networks maintained by sequence-specific RNA-RNA interactions
were identified for two viral strains [32,44]. The interacting sequences between two particular vRNAs
were precisely delineated, in vitro, by a combination of deletion analysis, antisense oligonucleotide
mapping and bioinformatics prediction of interacting sequences [44,54]. To confirm the existence
of the interaction in vitro, trans-complementary mutants on both vRNA were designed and tested.
This strategy, however, has its limitations as it is unknown whether all in vitro interactions take
place within the viral particles and conversely, whether all interactions that occur in virions can be
identified in vitro. Therefore, the relevance of in vitro identified vRNA-vRNA interactions and their
importance for selective co-packaging needs to be validated in an infectious context. To do so, the
phenotypic features (see Section 2.2) of the wild-type virus must be compared with those of each
single mutated virus (i.e., viruses bearing disrupting mutations in only one of the partner vRNAs),
and with those of a double-mutant virus bearing the trans-complementary mutations that restore the
interaction [54]. Packaging of vRNA can also be quantified directly by RT-qPCR (see Section 2.2) while
the importance of intersegment interaction to guide vRNA co-packaging can be tested by competitive
RG (see Section 3.1).
4. Conclusions
Reverse genetics has been extensively used to engineer IAVs in order to investigate the
mechanisms underlying packaging of their genome. Over the past ten years, remarkable progress was
made in understanding this process, based on a combination of genetic, imaging, and biochemical
complementary approaches. Recent data suggest that vRNPs could form sub-bundles in the
cytoplasm of infected cells whilst transported towards the plasma membrane in association with
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Rab-11-positive recycling endosomes (reviewed in [3]). In addition, the large set of data available
strongly suggests that subsequent packaging at the viral budding site is driven by the formation of
strain-specific supra-molecular complexes of eight distinct vRNPs held together by strain-specific
vRNA-vRNA interactions.
However, to confirm this model and further elucidate the molecular mechanisms involved, the
sensitivity, resolution, quantitative accuracy and/or statistical power of the methods being applied
need to be improved. Expanding the observations to various IAV strains including the novel bat
IAVs [58] and to influenza B [59] and C viruses will also help to get a comprehensive view of this
complex and versatile process. Work on other viruses with a segmented genome could also provide
valuable information. Interestingly, packaging of the reoviruses’ 11-segmented double-stranded RNA
genome is also believed to be sequential and mediated by RNA-RNA interactions [60]. An identical
workflow as the one described above for IAV, starting with in vitro identification of RNA-RNA
interactions up to the validation of the role of the interaction for efficient viral replication, was recently
used to decipher the packaging mechanism of Bluetongue virus [61].
Understanding the fundamental molecular mechanisms that underlie packaging of the IAV
genome is of the utmost importance since it should lead, in the long term, to a better understanding
of the mechanisms sustaining genetic reassortment of IAVs [9,38] and help to assess the likelihood of
the appearance of reassortant viruses, including those with pandemic potential. It might also help
to manipulate the genetic reassortment process in order to improve the generation, selection, and
production of high yielding vaccinal seeds [62].
Acknowledgments: We thank Martin Schwemmle, Sylvie van der Werf, Bernadette Crescenzo-Chaigne, Cyril
Barbezange, and Marion Declercq for comments on the manuscript. This study was supported by PREDEMICS
(Grant Agreement No. 278433).
Author Contributions: C.I., S.M. and N.N. wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Tomescu, A.I.; Robb, N.C.; Hengrung, N.; Fodor, E.; Kapanidis, A.N. Single-molecule FRET reveals a
corkscrew RNA structure for the polymerase-bound influenza virus promoter. Proc. Natl. Acad. Sci. USA
2014, 111, E3335–E3342. [CrossRef] [PubMed]
2. Eisfeld, A.J.; Neumann, G.; Kawaoka, Y. At the centre: Influenza A virus ribonucleoproteins.
Nat. Rev. Microbiol. 2015, 13, 28–41. [CrossRef] [PubMed]
3. Giese, S.; Bolte, H.; Schwemmle, M. The feat of packaging eight unique genome segments. Viruses 2016, 8,
165. [CrossRef] [PubMed]
4. Harris, A.; Cardone, G.; Winkler, D.C.; Heymann, J.B.; Brecher, M.; White, J.M.; Steven, A.C. Influenza virus
pleiomorphy characterized by cryoelectron tomography. Proc. Natl. Acad. Sci. USA 2006, 103, 19123–19127.
[CrossRef] [PubMed]
5. Noda, T.; Sagara, H.; Yen, A.; Takada, A.; Kida, H.; Cheng, R.H.; Kawaoka, Y. Architecture of
ribonucleoprotein complexes in influenza A virus particles. Nature 2006, 439, 490–492. [CrossRef] [PubMed]
6. Laver, W.G.; Downie, J.C. Influenza virus recombination. I. Matrix protein markers and segregation during
mixed infections. Virology 1976, 70, 105–117. [CrossRef]
7. Nakajima, K.; Sugiura, A. Three-factor cross of influenza virus. Virology 1977, 81, 486–489. [CrossRef]
8. Hutchinson, E.C.; von Kirchbach, J.C.; Gog, J.R.; Digard, P. Genome packaging in influenza A virus.
J. Gen. Virol. 2010, 91, 313–328. [CrossRef] [PubMed]
9. Gerber, M.; Isel, C.; Moules, V.; Marquet, R. Selective packaging of the influenza A genome and consequences
for genetic reassortment. Trends Microbiol. 2014, 22, 446–455. [CrossRef] [PubMed]
10. Engelhardt, O.G. Many ways to make an influenza virus—Review of influenza virus reverse genetics
methods. Influenza Other Respir. Viruses 2013, 7, 249–256. [CrossRef] [PubMed]
11. Fodor, E.; Devenish, L.; Engelhardt, O.G.; Palese, P.; Brownlee, G.G.; Garcia-Sastre, A. Rescue of influenza A
virus from recombinant DNA. J. Virol. 1999, 73, 9679–9682. [PubMed]
Viruses 2016, 8, 218 13 of 15
12. Neumann, G.; Watanabe, T.; Ito, H.; Watanabe, S.; Goto, H.; Gao, P.; Hughes, M.; Perez, D.R.;
Donis, R.; Hoffmann, E.; et al. Generation of influenza A viruses entirely from cloned cDNAs.
Proc. Natl. Acad. Sci. USA 1999, 96, 9345–9350. [CrossRef] [PubMed]
13. Hoffmann, E.; Neumann, G.; Kawaoka, Y.; Hobom, G.; Webster, R.G. A DNA transfection system for
generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 2000, 97, 6108–6113.
[CrossRef] [PubMed]
14. Gultyaev, A.P.; Fouchier, R.A.; Olsthoorn, R.C. Influenza virus RNA structure: Unique and common features.
Int. Rev. Immunol. 2010, 29, 533–556. [CrossRef] [PubMed]
15. Gultyaev, A.P.; Tsyganov-Bodounov, A.; Spronken, M.I.; van der Kooij, S.; Fouchier, R.A.; Olsthoorn, R.C.
RNA structural constraints in the evolution of the influenza A virus genome NP segment. RNA Biol. 2014,
11, 942–952. [CrossRef] [PubMed]
16. Lenartowicz, E.; Kesy, J.; Ruszkowska, A.; Soszynska-Jozwiak, M.; Michalak, P.; Moss, W.N.; Turner, D.H.;
Kierzek, R.; Kierzek, E. Self-folding of naked segment 8 genomic RNA of influenza A virus. PLoS ONE 2016,
11, e0148281. [CrossRef] [PubMed]
17. Baudin, F.; Bach, C.; Cusack, S.; Ruigrok, R.W. Structure of influenza virus RNP. I. Influenza virus
nucleoprotein melts secondary structure in panhandle rna and exposes the bases to the solvent. EMBO J.
1994, 13, 3158–3165. [PubMed]
18. Gog, J.R.; Afonso Edos, S.; Dalton, R.M.; Leclercq, I.; Tiley, L.; Elton, D.; von Kirchbach, J.C.; Naffakh, N.;
Escriou, N.; Digard, P. Codon conservation in the influenza A virus genome defines RNA packaging signals.
Nucleic Acids Res. 2007, 35, 1897–1907. [CrossRef] [PubMed]
19. Marsh, G.A.; Rabadan, R.; Levine, A.J.; Palese, P. Highly conserved regions of influenza A virus polymerase
gene segments are critical for efficient viral RNA packaging. J. Virol. 2008, 82, 2295–2304. [CrossRef]
[PubMed]
20. Watanabe, T.; Watanabe, S.; Noda, T.; Fujii, Y.; Kawaoka, Y. Exploitation of nucleic acid packaging signals
to generate a novel influenza virus-based vector stably expressing two foreign genes. J. Virol. 2003, 77,
10575–10583. [CrossRef] [PubMed]
21. Fujii, K.; Fujii, Y.; Noda, T.; Muramoto, Y.; Watanabe, T.; Takada, A.; Goto, H.; Horimoto, T.; Kawaoka, Y.
Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS
segment for its efficient incorporation into virions. J. Virol. 2005, 79, 3766–3774. [CrossRef] [PubMed]
22. Muramoto, Y.; Takada, A.; Fujii, K.; Noda, T.; Iwatsuki-Horimoto, K.; Watanabe, S.; Horimoto, T.; Kida, H.;
Kawaoka, Y. Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into
influenza A virions. J. Virol. 2006, 80, 2318–2325. [CrossRef] [PubMed]
23. Ozawa, M.; Fujii, K.; Muramoto, Y.; Yamada, S.; Yamayoshi, S.; Takada, A.; Goto, H.; Horimoto, T.;
Kawaoka, Y. Contributions of two nuclear localization signals of influenza A virus nucleoprotein to viral
replication. J. Virol. 2007, 81, 30–41. [CrossRef] [PubMed]
24. Liang, Y.; Hong, Y.; Parslow, T.G. Cis-acting packaging signals in the influenza virus PB1, PB2, and PA
genomic RNA segments. J. Virol. 2005, 79, 10348–10355. [CrossRef] [PubMed]
25. Marsh, G.A.; Hatami, R.; Palese, P. Specific residues of the influenza A virus hemagglutinin viral RNA are
important for efficient packaging into budding virions. J. Virol. 2007, 81, 9727–9736. [CrossRef] [PubMed]
26. Fujii, Y.; Goto, H.; Watanabe, T.; Yoshida, T.; Kawaoka, Y. Selective incorporation of influenza virus RNA
segments into virions. Proc. Natl. Acad. Sci. USA 2003, 100, 2002–2007. [CrossRef] [PubMed]
27. Hughes, M.T.; McGregor, M.; Suzuki, T.; Suzuki, Y.; Kawaoka, Y. Adaptation of influenza A viruses to cells
expressing low levels of sialic acid leads to loss of neuraminidase activity. J. Virol. 2001, 75, 3766–3770.
[CrossRef] [PubMed]
28. Gao, Q.; Brydon, E.W.; Palese, P. A seven-segmented influenza A virus expressing the influenza C virus
glycoprotein HEF. J. Virol. 2008, 82, 6419–6426. [CrossRef] [PubMed]
29. Hutchinson, E.C.; Curran, M.D.; Read, E.K.; Gog, J.R.; Digard, P. Mutational analysis of cis-acting RNA
signals in segment 7 of influenza A virus. J. Virol. 2008, 82, 11869–11879. [CrossRef] [PubMed]
30. Hutchinson, E.C.; Wise, H.M.; Kudryavtseva, K.; Curran, M.D.; Digard, P. Characterisation of influenza A
viruses with mutations in segment 5 packaging signals. Vaccine 2009, 27, 6270–6275. [CrossRef] [PubMed]
31. Liang, Y.; Huang, T.; Ly, H.; Parslow, T.G.; Liang, Y. Mutational analyses of packaging signals in influenza
virus PA, PB1, and PB2 genomic RNA segments. J. Virol. 2008, 82, 229–236. [CrossRef] [PubMed]
Viruses 2016, 8, 218 14 of 15
32. Fournier, E.; Moules, V.; Essere, B.; Paillart, J.C.; Sirbat, J.D.; Isel, C.; Cavalier, A.; Rolland, J.P.; Thomas, D.;
Lina, B.; et al. A supramolecular assembly formed by influenza A virus genomic RNA segments.
Nucleic Acids Res. 2012, 40, 2197–2209. [CrossRef] [PubMed]
33. Noda, T.; Sugita, Y.; Aoyama, K.; Hirase, A.; Kawakami, E.; Miyazawa, A.; Sagara, H.; Kawaoka, Y.
Three-dimensional analysis of ribonucleoprotein complexes in influenza A virus. Nat. Commun. 2012,
3, 639. [CrossRef] [PubMed]
34. Gao, Q.; Chou, Y.Y.; Doganay, S.; Vafabakhsh, R.; Ha, T.; Palese, P. The influenza A virus PB2, PA, NP, and M
segments play a pivotal role during genome packaging. J. Virol. 2012, 86, 7043–7051. [CrossRef] [PubMed]
35. Goto, H.; Muramoto, Y.; Noda, T.; Kawaoka, Y. The genome-packaging signal of the influenza A virus genome
comprises a genome incorporation signal and a genome-bundling signal. J. Virol. 2013, 87, 11316–11322.
[CrossRef] [PubMed]
36. Zhao, L.; Peng, Y.; Zhou, K.; Cao, M.; Wang, J.; Wang, X.; Jiang, T.; Deng, T. New insights into the
nonconserved noncoding region of the subtype-determinant hemagglutinin and neuraminidase segments of
influenza A viruses. J. Virol. 2014, 88, 11493–11503. [CrossRef] [PubMed]
37. Lakdawala, S.S.; Wu, Y.; Wawrzusin, P.; Kabat, J.; Broadbent, A.J.; Lamirande, E.W.; Fodor, E.;
Altan-Bonnet, N.; Shroff, H.; Subbarao, K. Influenza A virus assembly intermediates fuse in the cytoplasm.
PLoS Pathog. 2014, 10, e1003971. [CrossRef] [PubMed]
38. McDonald, S.M.; Nelson, M.I.; Turner, P.E.; Patton, J.T. Reassortment in segmented RNA viruses: Mechanisms
and outcomes. Nat. Rev. Microbiol. 2016, 14, 448–460. [CrossRef] [PubMed]
39. Li, C.; Hatta, M.; Watanabe, S.; Neumann, G.; Kawaoka, Y. Compatibility among polymerase subunit proteins
is a restricting factor in reassortment between equine H7N7 and human H3N2 influenza viruses. J. Virol.
2008, 82, 11880–11888. [CrossRef] [PubMed]
40. Jackson, S.; Van Hoeven, N.; Chen, L.M.; Maines, T.R.; Cox, N.J.; Katz, J.M.; Donis, R.O. Reassortment
between avian H5N1 and human H3N2 influenza viruses in ferrets: A public health risk assessment. J. Virol.
2009, 83, 8131–8140. [CrossRef] [PubMed]
41. Octaviani, C.P.; Ozawa, M.; Yamada, S.; Goto, H.; Kawaoka, Y. High level of genetic compatibility between
swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J. Virol. 2010, 84, 10918–10922.
[CrossRef] [PubMed]
42. Essere, B.; Yver, M.; Gavazzi, C.; Terrier, O.; Isel, C.; Fournier, E.; Giroux, F.; Textoris, J.; Julien, T.; Socratous, C.;
et al. Critical role of segment-specific packaging signals in genetic reassortment of influenza A viruses.
Proc. Natl. Acad. Sci. USA 2013, 110, E3840–E3848. [CrossRef] [PubMed]
43. Cobbin, J.C.; Ong, C.; Verity, E.; Gilbertson, B.P.; Rockman, S.P.; Brown, L.E. Influenza virus PB1 and
neuraminidase gene segments can cosegregate during vaccine reassortment driven by interactions in the
PB1 coding region. J. Virol. 2014, 88, 8971–8980. [CrossRef] [PubMed]
44. Gavazzi, C.; Isel, C.; Fournier, E.; Moules, V.; Cavalier, A.; Thomas, D.; Lina, B.; Marquet, R. An in vitro
network of intermolecular interactions between viral RNA segments of an avian H5N2 influenza A virus:
Comparison with a human H3N2 virus. Nucleic Acids Res. 2013, 41, 1241–1254. [CrossRef] [PubMed]
45. Ince, W.L.; Gueye-Mbaye, A.; Bennink, J.R.; Yewdell, J.W. Reassortment complements spontaneous mutation
in influenza A virus NP and M1 genes to accelerate adaptation to a new host. J. Virol. 2013, 87, 4330–4338.
[CrossRef] [PubMed]
46. Marshall, N.; Priyamvada, L.; Ende, Z.; Steel, J.; Lowen, A.C. Influenza virus reassortment occurs with high
frequency in the absence of segment mismatch. PLoS Pathog. 2013, 9, e1003421. [CrossRef] [PubMed]
47. Zeldovich, K.B.; Liu, P.; Renzette, N.; Foll, M.; Pham, S.T.; Venev, S.V.; Gallagher, G.R.; Bolon, D.N.;
Kurt-Jones, E.A.; Jensen, J.D.; et al. Positive selection drives preferred segment combinations during
influenza virus reassortment. Mol. Biol. Evol. 2015, 32, 1519–1532. [CrossRef] [PubMed]
48. Shcherbik, S.V.; Pearce, N.C.; Levine, M.L.; Klimov, A.I.; Villanueva, J.M.; Bousse, T.L. Rapid strategy for
screening by pyrosequencing of influenza virus reassortants—Candidates for live attenuated vaccines.
PLoS ONE 2014, 9, e92580. [CrossRef] [PubMed]
49. Chou, Y.Y.; Vafabakhsh, R.; Doganay, S.; Gao, Q.; Ha, T.; Palese, P. One influenza virus particle packages eight
unique viral RNAs as shown by FISH analysis. Proc. Natl. Acad. Sci. USA 2012, 109, 9101–9106. [CrossRef]
[PubMed]
Viruses 2016, 8, 218 15 of 15
50. Chou, Y.Y.; Heaton, N.S.; Gao, Q.; Palese, P.; Singer, R.H.; Lionnet, T. Colocalization of different influenza
viral RNA segments in the cytoplasm before viral budding as shown by single-molecule sensitivity FISH
analysis. PLoS Pathog. 2013, 9, e1003358. [CrossRef]
51. Lubeck, E.; Cai, L. Single-cell systems biology by super-resolution imaging and combinatorial labeling.
Nat. Methods 2012, 9, 743–748. [CrossRef] [PubMed]
52. Lubeck, E.; Coskun, A.F.; Zhiyentayev, T.; Ahmad, M.; Cai, L. Single-cell in situ RNA profiling by sequential
hybridization. Nat. Methods 2014, 11, 360–361. [CrossRef] [PubMed]
53. Crosetto, N.; Bienko, M.; van Oudenaarden, A. Spatially resolved transcriptomics and beyond.
Nat. Rev. Genet. 2015, 16, 57–66. [CrossRef] [PubMed]
54. Gavazzi, C.; Yver, M.; Isel, C.; Smyth, R.P.; Rosa-Calatrava, M.; Lina, B.; Moules, V.; Marquet, R. A functional
sequence-specific interaction between influenza A virus genomic RNA segments. Proc. Natl. Acad. Sci. USA
2013, 110, 16604–16609. [CrossRef] [PubMed]
55. Sugita, Y.; Sagara, H.; Noda, T.; Kawaoka, Y. Configuration of viral ribonucleoprotein complexes within the
influenza A virion. J. Virol. 2013, 87, 12879–12884. [CrossRef] [PubMed]
56. Arranz, R.; Coloma, R.; Chichon, F.J.; Conesa, J.J.; Carrascosa, J.L.; Valpuesta, J.M.; Ortin, J.; Martin-Benito, J.
The structure of native influenza virion ribonucleoproteins. Science 2012, 338, 1634–1637. [CrossRef]
[PubMed]
57. Moeller, A.; Kirchdoerfer, R.N.; Potter, C.S.; Carragher, B.; Wilson, I.A. Organization of the influenza virus
replication machinery. Science 2012, 338, 1631–1634. [CrossRef] [PubMed]
58. Juozapaitis, M.; Aguiar Moreira, E.; Mena, I.; Giese, S.; Riegger, D.; Pohlmann, A.; Hoper, D.; Zimmer, G.;
Beer, M.; Garcia-Sastre, A.; et al. An infectious bat-derived chimeric influenza virus harbouring the entry
machinery of an influenza A virus. Nat. Commun. 2014, 5, 4448. [CrossRef] [PubMed]
59. Sherry, L.; Punovuori, K.; Wallace, L.E.; Prangley, E.; DeFries, S.; Jackson, D. Identification of cis-acting
packaging signals in the coding regions of the influenza B virus HA gene segment. J. Gen. Virol. 2016, 97,
306–315. [CrossRef] [PubMed]
60. Fajardo, T., Jr.; Sung, P.Y.; Roy, P. Disruption of specific RNA-RNA interactions in a double-stranded RNA
virus inhibits genome packaging and virus infectivity. PLoS Pathog. 2015, 11, e1005321. [CrossRef] [PubMed]
61. Boyce, M.; McCrae, M.A.; Boyce, P.; Kim, J.T. Inter-segment complementarity in orbiviruses: A driver for
co-ordinated genome packaging in the Reoviridae? J. Gen. Virol. 2016, 97, 1145–1157. [CrossRef] [PubMed]
62. Elderfield, R.A.; Hartgroves, L.C.S.; Barclay, W.S. Using reverse genetics to improve influenza vaccines.
In Reverse Genetics of RNA Viruses; Bridgen, A., Ed.; Wiley-Blackwell: Hoboken, NJ, USA, 2013;
pp. 224–249.
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
